Rabeprazole And Domperidone Capsules By Facmed Pharmaceuticals Pvt. Ltd.

Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting the gastric H+/K+ ATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. The onset of action is 1 hour. Duration 24 hours. Absorption Oral bioavailability is about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin. The median inhibitory effect of rabeprazole on 24-hour gastric acidity is 88% of maximal after the first dose.

In fasting subjects, domperidone is rapidly absorbed after oral administration, with peak plasma concentrations at 30 to 60 minutes. The low absolute bioavailability of oral domperidone (approximately 15%) is due to extensive first-pass metabolism in the gut wall and liver. Although domperidone`s bioavailability is enhanced in normal subjects when taken after a meal, patients with gastrointestinal complaints should take domperidone 15-30 minutes before a meal. Reduced gastric acidity impairs the absorption of domperidone.

FORMULATIONS AVAILABLE: CAPSULE
Each Hard Gelatin Capsule contains:

Rabeprazole Sodium IP (as enteric coated) 20 mg

Domperidone Maleate IP (= to Domperidone) (10 mg as IR, 20 mg as SR) 30 mg

Domperidone Maleate IP (= to Domperidone) (10 mg as IR, 20 mg as SR) 30 mg

DOSAGE AND ADMINISTRATION: One capsule once daily.

INDICATIONS:
Rabeprazole & Domperidone Capsules is indicated for the relief of symptoms of dyspepsia
Nausea associated with acid peptic disorders
Post-operative nausea and vomiting
Chronic gastritis